FARMACOLOGIA

Doxorubicina

Cassinelli G. The roots of modern oncology: from discovery of new antitumor anthracyclines to their clinical use. Tumori. 2016 Jun 2;2016(3):226-35. 

Canevazzi,G. Grein A. Spalla C. Daunomicina: descrizione del microrganismo produttore e del metodo di produzione. In Aggiornamenti clinico terapeutici Farmitalia, La daunoblastina, Edizioni Minerva Medica 1970. 

Di Marco A. Attività biologica e meccanismo d’azione. In Aggiornamenti clinico terapeutici Framitalia, La daunoblatina, Edizioni Minerva Medica 1970. 

Cassinelli G, Orezzi P. La daunomicina: un nuovo antibiotico ad attività citostatica. Isolamento e proprietà. Giorn Microbiol. 1963;11:167-174.

Arcamone F. Cassinelli G. Franceschi G. Mondelli R. Orezzi P. Penco S. Struttura e stereochimica della daunomicina. Gazz Chim Ital. 1970;100:949-989. 

Silvestrini R. Dimarco A. Dimarco S. Dasdia T. Action of daunomycin on the metabolism of nucleic acids of normal and neoplastic cells growing in vitro. Tumori. 1963;49:399-411. 

Di Marco A. Gaetani M. Dorigotti L. Soldati M. Bellini O. Daunomycin: a new antibiotic with antitumor activity. Tumori. 1963;49:203-217. 

Di Marco A. G Cassinelli. F. Arcamone. The discovery of Daunorubicin. Cancer Treatment Reports 65 (Suppl. 4) 1981. 

Di Marco A. Mechanism of action of Daunomycin Acta Genet Med Gemellol (Roma). 1968;17(1):102-21. 

Italian Antibiotic inhibits cancer, Staph. Science News Letter, 85 134, 1964. 

Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967;20(3):333-353. 

Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C., Spalla C. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng. 1969;11(6):1101-1110. 

Arcamone F, Cassinelli G, Franceschi G. Penco S. Pol C., Redaelli S. Selva A. Structure and Physicochemical properties of Adriamycin (Doxorubicin). International Symposium on Adriamycin. Springer-Verlag Berlin Heildelberg New York 1972. 

Arcamone F, Franceschi G, Penco S, Selva A. Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic. Tetrahedron Lett. 1969;13(13):1007-1010. 

Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F. Clinical evaluation of adriamycin, a new antitumour antibiotic. Br Med J. 1969 Aug 30;3(5669):503-6. 

Monfardini S, Bonadonna G, Di Pietro S, Guindani A, Fossati-Bellani F, De Lena M. Sperimentazione clinica preliminare con adriamicina in pazienti affetti da leucemi e tumori solidi in fase avanzata [Clinical trials with adriamycin in leukemia and solid tumors]. Tumori. 1969;55(4):197-216. Italian. 

Bonadonna G, Beretta G, Tancini G, De Lena M, Monfardini S, Bajetta E, Fossati Bellani F, Brambilla C, Veronesi U. Polichemioterapia con adriamicina in varie forme tumorali [Adriamycin in combination and in combined treatment modalities (author’s transl)]. Tumori. 1974 Sep-Oct;60(5):393-416. Italian. 

Carter SK, Di Marco A, Ghione M, Krakoff IH, Mathè G, eds. International Symposium on Adriamycin. Springer-Verlag, Berlin and New York, 1972.

Bonadonna G. Schiavi G. Medici umani, pazienti guerrieri. La cura è questa.  In Saggi Baldini Castoldi Dalai Editore, Milano 2008. 

Bonadonna G, Valagussa P. C’era una volta… in Bonadonna G, ed. Una guerra da vincere. Guerrini e Associati Milano, 2010.  

Minerva D, Monfardini S, Il bagnino e i sette samurai. La ricerca biomedica in Italia. Edizioni Codice, Torino, 2013.

WHO Technical Report Series, No. 615. The Selection of Essential Drugs (1977) – TRS 615. 

WHO Model List of Essential Medicines – 23rd list, 2023.

p53

Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., & Zunino, F. (1996). Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer research, 56(3), 556–562. 

Lavarino, C., Pilotti, S., Oggionni, M., Gatti, L., Perego, P., Bresciani, G., Pierotti, M. A., Scambia, G., Ferrandina, G., Fagotti, A., Mangioni, C., Lucchini, V., Vecchione, F., Bolis, G., Scarfone, G., & Zunino, F. (2000). p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18(23), 3936–3945. 

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023). Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal transduction and targeted therapy, 8(1), 92. 

Manic, S., Gatti, L., Carenini, N., Fumagalli, G., Zunino, F., & Perego, P. (2003). Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Current cancer drug targets, 3(1), 21–29. 

Inibitore RET RPI-1

Lanzi C, Cassinelli G, Pensa T, Cassinis M, Gambetta RA, Borrello MG, Menta E, Pierotti MA, Zunino F. Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative. Int J Cancer. 2000 Feb 1;85(3):384-90. 

Lanzi C, Cassinelli G, Cuccuru G, Zaffaroni N, Supino R, Vignati S, Zanchi C, Yamamoto M, Zunino F. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci. 2003 Jul;60(7):1449-59. 

Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst. 2004 Jul 7;96(13):1006-14. 

EDITORIAL: Wells SA, Nevins JR. Evolving strategies for targeted cancer therapy–past, present, and future. J Natl Cancer Inst. 2004 Jul 7;96(13):980-1. 

Petrangolini G, Cuccuru G, Lanzi C, Tortoreto M, Belluco S, Pratesi G, Cassinelli G, Zunino F. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol. 2006 Aug 14;72(4):405-14. 

Telomeri

Maciejewska N, Olszewski M, Jurasz J, Baginski M, Stasevych M, Zvarych V, Folini M, Zaffaroni N. Teloxantron inhibits the processivity of telomerase with preferential DNA damage on telomeres. Cell Death Dis. 2022 Nov 28;13(11):1005.

Alessandrini I, Percio S, Naghshineh E, Zuco V, Stacchiotti S, Gronchi A, Pasquali S, Zaffaroni N, Folini M. Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma. Cancers (Basel). 2022 May 25;14(11):2624. 

Folini M, Venturini L, Cimino-Reale G, Zaffaroni N. Telomeres as targets for anticancer therapies. Expert Opin Ther Targets. 2011 May;15(5):579-93. 

Modelli preclinici

Stacchiotti S, Tortoreto M, Bozzi F, Tamborini E, Morosi C, Messina A, Libertini M, Palassini E, Cominetti D, Negri T, Gronchi A, Pilotti S, Zaffaroni N, Casali PG. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics. Clin Cancer Res. 2013 Sep 15;19(18):5192-201. 

Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG, Zaffaroni N. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. Eur J Cancer. 2014 Nov;50(17):3021-8.

Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D’Incalci M, Zaffaroni N. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. Eur J Cancer. 2017 May;76:84-92.

Stacchiotti S, Zuco V, Tortoreto M, Cominetti D, Frezza AM, Percio S, Indio V, Barisella M, Monti V, Brich S, Astolfi A, Colombo C, Pasquali S, Folini M, Gounder MM, Pantaleo MA, Collini P, Dei Tos AP, Casali PG, Gronchi A, Zaffaroni N. Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft. Cancers (Basel). 2019 Jul 19;11(7):1015. 

Zuco V, Pasquali S, Tortoreto M, Brich S, Percio S, Dagrada GP, Colombo C, Sanfilippo R, Lauricella C, Gounder M, El Bezawy R, Barisella M, Dei Tos AP, Casali PG, Gronchi A, Stacchiotti S, Zaffaroni N. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation. J Exp Clin Cancer Res. 2021 Mar 1;40(1):83. 

Sviluppo di farmaci

Arcamone, F., Animati, F., Berettoni, M., Bigioni, M., Capranico, G., Casazza, A. M., Caserini, C., Cipollone, A., De Cesare, M., Franciotti, M., Lombardi, P., Madami, A., Manzini, S., Monteagudo, E., Polizzi, D., Pratesi, G., Righetti, S. C., Salvatore, C., Supino, R., & Zunino, F. (1997). Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. Journal of the National Cancer Institute, 89(16), 1217–1223. 

Pratesi, G., De Cesare, M., Caserini, C., Perego, P., Dal Bo, L., Polizzi, D., Supino, R., Bigioni, M., Manzini, S., Iafrate, E., Salvatore, C., Casazza, A., Arcamone, F., & Zunino, F. (1998). Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research, 4(11), 2833–2839. 

Perego, P., De Cesare, M., De Isabella, P., Carenini, N., Beggiolin, G., Pezzoni, G., Palumbo, M., Tartaglia, L., Pratesi, G., Pisano, C., Carminati, P., Scheffer, G. L., & Zunino, F. (2001). A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer research, 61(16), 6034–6037.

Zuco, V., Supino, R., Favini, E., Tortoreto, M., Cincinelli, R., Croce, A. C., Bucci, F., Pisano, C., & Zunino, F. (2010). Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma. Biochemical pharmacology, 79(4), 535–541. 

Pisano, C., De Cesare, M., Beretta, G. L., Zuco, V., Pratesi, G., Penco, S., Vesci, L., Foderà, R., Ferrara, F. F., Guglielmi, M. B., Carminati, P., Dallavalle, S., Morini, G., Merlini, L., Orlandi, A., & Zunino, F. (2008). Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968. Molecular cancer therapeutics, 7(7), 2051–2059. 

Cassinelli, G., Zuco, V., Petrangolini, G., De Cesare, M., Tortoreto, M., Lanzi, C., Cominetti, D., Zaffaroni, N., Orlandi, A., Passeri, D., Meco, D., Di Francesco, A. M., Riccardi, R., Bucci, F., Pisano, C., & Zunino, F. (2012). The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects. Biochemical pharmacology, 84(2), 163–171. 

Beretta, G. L., Petrangolini, G., De Cesare, M., Pratesi, G., Perego, P., Tinelli, S., Tortoreto, M., Zucchetti, M., Frapolli, R., Bello, E., Manzotti, C., Fontana, G., Bombardelli, E., Battaglia, A., Samorì, C., & Zunino, F. (2006). Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring. Cancer research, 66(22), 10976–10982. 

Perego, P., Caserini, C., Gatti, L., Carenini, N., Romanelli, S., Supino, R., Colangelo, D., Viano, I., Leone, R., Spinelli, S., Pezzoni, G., Manzotti, C., Farrell, N., & Zunino, F. (1999). A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Molecular pharmacology, 55(3), 528–534. 

Pratesi, G., Perego, P., Polizzi, D., Righetti, S. C., Supino, R., Caserini, C., Manzotti, C., Giuliani, F. C., Pezzoni, G., Tognella, S., Spinelli, S., Farrell, N., & Zunino, F. (1999). A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. British journal of cancer, 80(12), 1912–1919. 

Cassinelli, G., Lanzi, C., Supino, R., Pratesi, G., Zuco, V., Laccabue, D., Cuccuru, G., Bombardelli, E., & Zunino, F. (2002). Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 8(8), 2647–2654. 

Pratesi, G., Perego, P., Polizzi, D., Righetti, S. C., Supino, R., Caserini, C., Manzotti, C., Giuliani, F. C., Pezzoni, G., Tognella, S., Spinelli, S., Farrell, N., & Zunino, F. (1999). A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. British journal of cancer, 80(12), 1912–1919. 

Chemioprevenzione

Formelli F, Camerini T, Cavadini E, Appierto V, Villani MG, Costa A, De Palo G, Di Mauro MG, Veronesi U. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome. Cancer Epidemiol Biomarkers Prev. 2003 Jan;12(1):34-41. 

Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, Miceli R, Di Mauro MG, Costa A, Marubini E, Sporn MB, De Palo G. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol. 2006 Jul;17(7):1065-71.